A Bec 300mg (Abacavir)

DESCRIPTION

A Bec 300mg (Abacavir 300mg) belongs to type of classification of antiretroviral drug in which combination of tablet that contains ingredients like Abacavir A Bec 300mg (Abacavir 300mg) involves in the inhibition of HIV-type I infection, it will combine with other anti-retroviral medicines to regulate the infections.

it is active against HIV viruses which definitely inhibit it from progressing to AIDS.

INDICATION

A Bec 300mg (Abacavir 300mg) tablet is indicated for the treatment of patients suffering from HIV type I infection patients.

MECHANISM OF ACTION

Abacavir is a type includes in nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analogue), which has activity against human immunodeficiency virus type I. Abacavir is converted into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP by phosphorylated This active metabolite interfere with the action of reverse transcriptase by competing with dGTP and fused into viral DNA The development of viral DNA gets concerned by infusion of nucleotide which leads to lack of OH molecule. OH molecules are specific for the formation of 5’ to 3’ phosphodiester linkage which is required for chain elongation.

PHARMACOKINETIC

Absorption

Abacavir and is highly absorbed after oral administration and its bioavailability occurs at 83% and 87% respectively

Distribution

The drug Abacavir bound to human plasma protein nearly 50%;

Metabolism

Abacavir metabolism occurred by alcohol dehydrogenase and glucuronyl transferase.

Elimination

The terminal half life of abacavir is 1.54±0.63 hours

DOSAGE MANAGEMENT

The usual dose of A Bec 300mg (Abacavir 300mg) tablet is one tablet of abacavir 300mg which to be taken orally as a single dose, in combination with other anti-retroviral medicines with or without food.

SIDE EFFECTS

Fatal hypersensitivity reactions Lactic acidosis and severe hepatomegaly with steatosis Exacerbations of hepatitis B Hepatic decompensated in patients co-infected with HIV-I and hepatitis C Immune reconstitution syndrome Fat redistribution Myocardial infraction Some common side effects; Insomnia, depression, headache, fatigue, dizziness, rash, pyrexia, abdominal pain, abnormal pain, anxiety

DRUG INTERACTION

Zalcitabine, it is not concomitant with A Bec 300mg (Abacavir 300mg) because the effect of lamivudine which is present in the drug and Zalcitabine are inhibits each other. If taking getting methadone maintenance therapy, with abacavir 600mg twice daily leads to increase the methadone clearance HLA-B*5701 allele not co administered with abacavir due to anaphylactic reactions occurs Ethanol blocks the ability of the kidney to eliminate the drug abacavir

CONTRAINDICATION

 A Bec 300mg (Abacavir 300mg) tablets are contraindicated in the patients having HLA-B 5701 allele Hypersensitivity reaction to components present in the product Severe hepatic impairment

PRECAUTION

Caution with if patients having; Hypersensitivity reactions, lactic acidosis, severe hepatomegaly with steatosis and exacerbations of hepatitis B Fat redistribution, myocardial infarction, hepatic impairment

PREGNANCY & LACTATION

Pregnancy category C: A Bec 300mg (Abacavir 300mg) causes birth defects to unborn babies The use of A Bec 300mg (Abacavir 300mg) in pregnant women may have warrant in use Breastfeeding mothers should not take A Bec 300mg (Abacavir 300mg) , it excreted in human milk Nursing mothers not give milk to the babies; it might have chance of postnatal transmission.

STORAGE

The storage condition of A Bec 300mg (Abacavir 300mg) tablets are at room temperature 20°C to 25°C and keep it in dry place It should be keep away from moisture, heat, and light

MISSED DOSE

If patient not taken Tablet A Bec 300mg (Abacavir 300mg) , then the dose should be administered within the time The particular dose should be skipped and continue the next drug schedule